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Tele-monitored tDCS rehabilitation:
feasibility, challenges and future
perspectives in Parkinson’s disease
Alberto Cucca1, Kush Sharma1, Shashank Agarwal2, Andrew Seth Feigin1 and Milton Cesar Biagioni1*
Abstract
Transcranial direct current stimulation (tDCS) is a modality of non-invasive brain stimulation involving the application of
low amplitude direct current via surface electrodes on the scalp. tDCS has been studied in healthy populations and in
multiple brain disorders and has the potential to be a treatment for several neuropsychiatric conditions by virtue of its
capability of influencing cognitive, motor and behavioral processes. tDCS is a generally safe technique when performed
within standardized protocols in research or clinical settings. Furthermore, tDCS portability, high acceptability and user-
friendly interface makes it highly appealing for telemedicine practices. The term “telemedicine” refers to the procedures,
educational strategies, and care services that are remotely administered by means of different communication
technologies, with the final goal of increasing access to care for individuals and for improving public health. The
use of telemedicine combined with tDCS protocols is increasing, although the safety of this approach in different
clinical settings awaits further assessment. While “do-it-yourself” tDCS should be discouraged due to the unknown risk
of adverse events, the implementation of tele-monitored tDCS (tele-tDCS) within standardized frameworks ensuring
safety, tolerability, and reproducibility may allow this technology to reach larger clinical populations and bypass some
of the common barriers preventing access to health services and clinical trials. This review will discuss the current
evidence supporting the feasibility of tele-tDCS paradigms and their therapeutic potential, with particular emphasis on
the implications for patients with Parkinson’s disease.
Keywords: Telemedicine, Transcranial direct current stimulation, Neuro-rehabilitation, Parkinson’s disease
Introduction
The past decade of this century has been marked by the
steady development of new technologies that are now
able to connect broad sectors of populations to medical
providers and health care institutions. The term “tele-
medicine” (i.e. healing at a distance) encompasses a broad
range of telecommunication technologies that allow for
health services to be delivered remotely [1]. These services
include, among others, the administration of diagnostic
assessments, clinical monitoring, prevention strategies,
therapeutic supervision, education, consultation and psy-
chological support [2]. The obvious advantage of telemedi-
cine is the possibility of circumventing logistic barriers of
face-to-face health services by increasing accessibility for
people with disability and for those living in remote geo-
graphic areas with poor access to healthcare facilities [3].
There are further potential advantages related to the
implementation of telemedicine protocols. These include
the possibility of providing real-time monitoring of ad-
verse events, facilitating therapeutic compliance, reducing
social disparities in the access to care, promoting patients’
active role in diagnostic and therapeutic processes, and re-
ducing waiting time and economic burden, particularly for
people affected by chronic illnesses [4, 5]. Eventually, the
applications of telemedicine may involve monitoring mul-
tiple symptoms remotely by means of portable devices,
with relevant therapeutic implications, especially for clin-
ically fragile populations [6].
On the other hand, the rapid development of telemedi-
cine poses radical new challenges. The intensive exchange
of medical information through different platforms carries
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potential risks related to loss of confidentiality on large
volumes of sensitive data. These risks must be minimized
by implementing appropriate data protection strategies
[7]. Further, while telemedicine may potentially allow ac-
cess to larger populations, including individuals eligible
for research trials, the prerequisite of a subject’s ability to
use telecommunications may introduce a systematic selec-
tion bias leading to the exclusion of those sectors of the
population with poor or no technological skills. Although
age and familiarity with technology do not necessarily in-
fluence the access to telemedicine, it has been shown that
exposure to telemedicine practices does correlate with the
level of technological confidence [8].
Nevertheless, in the past years, the availability of
technology-enabled communications has grown dra-
matically and their cost/effectiveness has improved
accordingly. As a result, the remote administration of
diagnostic and therapeutic procedures has become a
widely consolidated clinical practice in different medical
fields, including urgent care, robotic surgery, imaging and
physical rehabilitation [9–12]. Recently, our center has
completed an interdisciplinary and home-based model for
a population with Parkinson’s Disease (PD) [13]. In these
patients, access to specialized care has been shown to de-
cline dramatically as the disease progresses, mainly due to
cumulative physical disability compounded by several psy-
chosocial factors [14]. Indeed, the lack of access to special-
ized care delivered by appropriately trained physicians has
been linked to increased morbidity, mortality and health-
care costs [13].
Transcranial direct current stimulation (tDCS) is an
investigational device broadly used in experimental and
clinical neuroscience with a wide range of potential
therapeutic applications. To date, tDCS has been applied
for the study and treatment of several conditions by
virtue of its capability of influencing cognitive, motor
and behavioral processes related to the pathophysiology
of different brain disorders [15]. One of the most signifi-
cant advantages of tDCS over other methods of
non-invasive brain stimulation (NIBS) is its portability,
low cost and safety [16]. Furthermore, due to its favor-
able tolerability and easier applicability, tDCS could be
easily incorporated into telemedicine-based protocols by
means of specialized devices that are designed for tele-
monitored tDCS (tele-tDCS) [17]. The development of
tele-tDCS interventions in clinical research holds great
potential by removing accessibility barriers, supporting a
greater number of subjects in research studies and enab-
ling the possibility to introduce patients largely under-
represented in research, including those burdened by
greater morbidity or by being homebound. Lastly, the
rigorous administration of tele-tDCS research protocols
involving customized devices and headgear may improve
the rate of recruitment, reduce attrition, relieve patients’
burden and increase cost/efficacy while maintaining clin-
ical trial standards.
The aim of this narrative review is to present the
reader with the latest evidence supporting the feasibility
of tele-tDCS paradigms and the potential near future ap-
plications of this technique for both experimental and
clinical purposes. Finally, the specific challenges and the-
oretical implications for patients affected by PD will be
critically discussed.
Telemedicine-based tDCS protocols
tDCS, essentials
tDCS is a modality of NIBS involving the application of
a low amplitude direct current (DC) via surface electrodes
on the scalp for a predetermined time in a relatively safe
manner. In tDCS, the cerebral cortex is stimulated through
a continuous, weak current (usually 1 to 2.5mA) which
alters brain function by changing the neuronal resting
membrane potential to either cause depolarization (under
the anode) or hyperpolarization (under the cathode) [18].
The principal mechanism of action of tDCS is a subthresh-
old modulation of neuronal membrane potentials, thus
modulating spontaneous neuronal firing activity depending
on the previous physiological state of the brain target area
[19, 20]. Additional mechanisms of action include the pos-
sibility to harness neuroplasticity through long-term po-
tentiation (LTP) and long-term depression mechanisms
(LTD) as well as to modify functional connectivity through-
out distributed cortico-subcortical networks, etc. [21, 22].
Although the exact mechanisms underlying tDCS effects
are not fully known at a molecular level, growing evidence
suggests non-linear effects mediated, at least partially, by lo-
calized shifts of intracellular Ca2+ concentration [23, 24].
Growing evidence accumulated through randomized
controlled trials (RCT) supports the potential of tDCS for
the treatment of various disorders, such as chronic pain,
fatigue, cognitive abnormalities, substance-related disor-
ders, and depression [25]. Many of these therapeutic areas
are relevant to patients burdened by chronic neurological
diseases, physical disability, or those that are homebound.
The safety of this technique has been addressed and tested
by multiple researchers who have concluded that tDCS, as
applied and monitored in compliance to the international
safety guidelines, is a safe and well-tolerated intervention
[26]. However, the safety and tolerability of tDCS on more
vulnerable populations and tele-tDCS paradigms remain
to be fully elucidated.
Rationale and pre-requisites for tele-monitored tDCS
A major limitation to the extensive clinical application of
NIBS protocols has been that most research studies have
involved small sample sizes and short duration, resulting
in trials without proper power analysis and predefined
intention to treat designs. The large majority of available
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trials has indeed involved a limited number of sessions
and participants as both clinicians and investigators face
challenges in the recruitment and retention of participants
in large-scale NIBS trials [27–30]. From the patient’s
perspective, the need to undergo multiple, consecutive
sessions spanning weeks or months can be particularly
cumbersome, especially in presence of highly disabling
symptoms [19]. Adapting tDCS technology for an easy
at-home use while meeting rigorous standards of experi-
mental reproducibility and safety monitoring could make
this intervention more suitable for larger research studies
involving a broader patient population.
One prerequisite to tele-tDCS is the availability of
equipment specifically designed to allow for remote use
and a customized headset for easy and reliable place-
ment of the electrodes. Simply utilizing the same devices
designed to be operated by health professionals may
compromise subject safety and affect experimental re-
producibility since inter-individual differences in techno-
logical skills and environments may not be adequately
addressed [31]. Customized devices for remote usage
should include clear instructions regarding the operation
of the device and the adequate setup of headset and
electrodes montage [32] (Table 1). The headgear should
be designed to allow simple and consistent placement of
the electrode at the desired location, thus facilitating re-
liable setup (for example, the headset can be labeled in
different colors to confirm that cables and electrodes are
properly matched). Special markers should be used to
ensure that the headset fits reliably on subject’s head,
while friendly usable (size-fitted) head straps or caps
should be provided to hold the sponge electrodes in a
still position throughout the duration of each session. In
Fig. 1 we describe a typical experimental tele-tDCS de-
vice designed for remote use in all its components.
In addition to dedicated devices, tele-tDCS should em-
ploy an adequate level of control by specifically trained
research staff or expert clinical professionals. On this
topic, “do it yourself” (DIY) tDCS practices should be
highly discouraged in light of the inherent risks involv-
ing subject’s safety and experimental reproducibility [33].
Visual confirmation obtained via HIPAA-compliant vid-
eoconferencing can be used to ensure proper set up and
control for contact quality while meeting optimal stan-
dards of data handling and confidentiality. Dedicated
training via instruction manual and demonstration video
should also be considered to further maximize the
chances of optimal electrode placement.
Experimental challenges with tele-monitored tDCS trials
The biological effects of tDCS, as any other NIBS tech-
nique, are essentially determined by two factors: extrin-
sic (related to the intervention) and intrinsic (related to
the stimulated subject) [34]. Extrinsic factors are related
to the amount of energy, the pattern of current flow and
the number on sessions delivered to the brain. In tDCS,
these include the electrode characteristics, the technical
Table 1 Steps, challenges, and solutions for daily remotely supervised tDCS (RS-tDCS) sessions. Modified from Riggs et al. with
authors’ permission [33]
Step Challenge Solution
1. Having all supplies available and
ready
Losing or misplacing Supplies Bountiful supply of pads with proper package of the tool box
2. Connecting to the internet A stable internet connection The Wi-Fi password readily available and troubleshooting any
problems being faced
3. Starting video conference with
remote control
Providing the study personnel with the
required password
Phone call beforehand for the required password for remote
connection
4. Attaching electrodes Improper attachment without alignment Each step clearly illustrated in the patient instructional video with
remote supervising
5. Proper placement of head strap Improper location
6. Preparing the device Not clear identification of each keypad
button with each step
7. Checking contact quality Understanding contact quality grade Lay language words, correcting any issues with study personnel
for improving contact quality
8. Starting the stimulation Using the correct start code provided by
study personnel
Lay language terms and instructional video on how to start
stimulation
9. Computer-based cognitive
training
Understanding and learning each game Lay Language and positive reinforcement for each game played
10. Ending the stimulation Hearing the beeping sound Informing patient the session is over
11. Clean up of the electrodes Proper cleaning of electrodes to avoid
corrosion
Teaching the patient on how and where to clean the saline
solution
12. Charging battery Charging battery as needed Step by step manner in instructional videos on how to charge the
device
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preparation and the device-controlled voltage waveform
[35]. However, for the same dose of energy delivered,
different intrinsic factors of the subject contribute to the
individuals’ biological outcome, including the pharmaco-
logical profile, age, gender, genetic characteristics, brain
state, the subject’s circadian rhythm, etc. [36].
In general, the best way to ensure consistent and reliable
electrode placement is to implement video-supervised ses-
sions during which the user, with or without caregivers,
are followed in real time by study personnel until elec-
trodes are properly placed and adequate contact is con-
firmed. Indeed, tele-tDCS protocols have consistently
showed optimal adherence, high tolerability and uni-
formity across sessions, while self-administered tDCS
without any degree of supervision has been associated
with a high dropout rate [37, 38].
As far as the device-controlled voltage waveform is in-
volved, the so-called “hardware approach” involves the
administration of a pre-determined voltage by pro-
grammed devices operating for a limited number of ses-
sions. After completion of the last session, the device no
longer provides any output. Alternatively, in the so-called
“software approach”, each tDCS session is enabled with a
pre-set duration and intensity by a specific code provided
to the user and/or caregiver by the research staff. After a
single session, the device remains inactive until a new
code is provided to unlock the next session [39].
In 2015, Charvet et al. proposed a standardized frame-
work for trials utilizing a tele-tDCS protocol defined as
“remotely-supervised tDCS” (RS-tDCS) in order to ensure
the same level of uniformity, compliance and reproducibil-
ity that would be expected by tDCS sessions administered
in the clinic [39]. This protocol included dedicated train-
ing of staff, user and/or caregiver, assessment of the user’s
capability to participate in tDCS remotely, checklist of
simple procedures for safe placement of electrodes and
headgear, strict dose control, monitoring of compliance
and adverse events, and clear guidelines for discontinu-
ation of sessions and/or study participation. In our studies,
we utilize a modified version of the proposed workflow al-
gorithm by Kasschau, Charvet and colleagues that is sum-
marized in Fig. 2 [40].
Shaw et al. analyzed the feasibility and tolerability of a
remotely supervised protocol involving anodal tDCS
over left dorsolateral prefrontal cortex (DLPFC) paired
with computer-based cognitive training [41]. The authors
pooled the available evidence from three distinct patient
populations: 26 participants with multiple sclerosis (MS)
undergoing an open-label study, 20 MS participants in a
randomized, double-blind, sham-controlled trial, and six
patients with PD who were recruited. A total of 748 RS
sessions were successfully completed in approximately 1
year, with adverse events not exceeding well-known mild
side effects of transient burning sensations of skin, tin-
gling, or itching being the most commonly reported.
Overall, these findings supported the feasibility and safety
of RS-tDCS as well as its potential generalizability to dif-
ferent patient populations. However, it should be noted
that the feasibility of different and/or more complex mon-
tages, for example high definition tDCS, remains to be
determined.
While protocols involving the remote use of tDCS
should be structured enough to ensure reproducibility and
safety, certain population-specific considerations should
also be made when applying tele-tDCS to patients with
different clinical profiles. Charvet et al. provided some
examples of these population-specific adaptations, where
peculiar issues encountered while delivering RS-tDCS in
people affected by attention-deficit/hyperactivity disorder,
depression, multiple sclerosis, and severe chronic illnesses
requiring palliative care were critically discussed [39]. It
is likely that the capability of a subject who was initially
Fig. 1 Example of tele-monitored tDCS (tele-tDCS) setup including the tDCS device (for at-home sessions), head strap and the videoconferencing
platform. The depicted tDCS device is a Soterix Mini-CT tDCS. The device delivers direct electrical current through saline-soaked sponge
electrodes (5 cm × 5 cm) snapped to a custom-made head strap. The head strap has clear labeling for reliable electrode placement (right picture).
This configuration provided a uniform bi-hemispheric dorsolateral prefrontal cortex montage centered using a nasion marker. The supervising
study technician is shown in the laptop screen (left picture) as a study participant would see it during video-conferencing
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deemed eligible to undergo tele-tDCS may fluctuate
over time in relation to his/her cognitive, behavioral
and physical symptoms. This is particularly relevant for
patients suffering from chronic mood disorders or cognitive
abnormalities. In patients with PD, a peculiar challenge to
tele-tDCS may be posed by the presence of motor and
non-motor fluctuations. Overall, population-specific con-
siderations should always be incorporated into tele-tDCS
designs, for example by including a flexible involvement of
subjects’ caregivers and/or an adaptive monitoring of po-
tential technical issues encountered during trial conduct.
Feasibility of tele-monitored tDCS for neurologic disorders
The available evidence supporting the telemedicine-based
use of tDCS remains limited to small exploratory trials
showing significant heterogeneity in terms of patient popu-
lations, primary outcome, and experimental design. In
2018, Palm et al. conducted a systematic review including
available protocols and original research involving the
home use of tele-tDCS for the treatment of various neuro-
psychiatric disorders [38]. From five RCT, three open label
studies and four case reports the overall rate of side effects
did not exceed those commonly observed with conven-
tional tDCS in lab settings operating within the inter-
national safety lines. Regular visits and remote conferences
by means of different communication technologies seemed
critical in ensuring the correct performance of stimulation
and minimizing attrition. The blinding integrity of con-
trolled studies appeared to be optimal, with no significant
differences in guesses for active or sham treatments. Palm
et al. evaluated the overall experimental quality of the RCT
determined by adherence to the proposed protocol, tech-
nical quality of stimulation, including electrode placement
and dose delivery, safety monitoring and adverse events
handling, modality of data storage, strategies to foster ad-
herence and capture meaningful clinical changes. Out of
the included RCT trials, only one fulfilled all of the above
parameters. More specifically, this RCT of André et al., re-
ported specific improvements in executive functions in 21
patients affected by vascular dementia undergoing four ses-
sions of anodal at-home tDCS over the right DLPFC [42].
Furthermore, Palm et al. proposed a new nomenclature
to highlight the methodological differences between differ-
ent uses of tele-tDCS. More specifically, the authors pro-
posed a distinction between a “domiciliary use” of tDCS
for compassionate or interventional purposes, in which
stimulation parameters are advised by the medical staff
but remain entirely dependent on patient’s compliance, vs
a “remotely supervised use”, in which the patient or the
caregiver activates a preprogrammed device secured
Fig. 2 Algorithm diagram with stop criteria for tele-monitored tDCS. Modified version from Kasschau et al. with authors’ permission. This protocol
included user and/or caregiver capability to participate in tDCS, check list of procedures for safe placement of electrodes and head strap, dose
control, monitoring of compliance and adverse events, and clear guidelines for discontinuation of sessions and/or study participation. Note
various stop criteria determining when a subject is no longer able to safely participate in the study
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against manipulation. In remotely supervised protocols,
supervision is offered by means of different technological
platforms (telephone, videoconferencing, email, smart-
phone applications, etc.) in order to overcome potential
technical difficulties and ensure optimal adherence. A
third identified setting is the “remotely controlled tDCS”,
in which the device, while still operated by patients or
caregivers, remains under constant remote control of the
medical staff. Regardless of its practical implications, this
nomenclature reflects the need to refine the terminology
used in the various trials to foster a greater experimental
uniformity and facilitate the systematic analysis of the
available data. Additionally, while the evidence supporting
the safety and feasibility of tele-tDCS is gradually emer-
ging, the efficacy of this new modality of neuromodulation
remains to be validated though well-powered, well de-
signed studies.
Tele-monitored tDCS in Parkinson’s disease
Telemedicine and movement disorders
Neurodegenerative diseases, particularly movement disor-
ders, are known to be characterized by chronic, progres-
sive disability and reduced mobility. These conditions are
frequently compounded by a number of psychosocial fac-
tors that can further reduce both accessibility and adher-
ence to medical care. Furthermore, in certain geographical
and socioeconomic backgrounds, the effective care of
movement disorders is hindered by the scarcity of specif-
ically trained health care professionals as well as by limited
access to dedicated facilities [43].
PD is the second most common neurodegenerative
disorder after Alzheimer’s Dementia. Given the current
demographic trend, the global burden of PD will increase
rapidly, particularly in those developing economies where
access to care is more limited [44]. It was recently observed
that the majority of individuals with PD have a very limited
access to care, with more than 40% of patients lacking
appropriate neurologic care in the United States [45]. Even
among individuals initially receiving dedicated and/or inter-
disciplinary medical attention the cumulative disability
related to the disease progression may eventually lead to a
homebound status that compromises access to specialized
care. Furthermore, PD patients may be more likely to be
lost to follow-up because of common comorbidities such as
fatigue, mood disorders, apathy, and anxiety as well as by
the onset of complications related to the prolonged
pharmacological treatment such as motor fluctuations
and dyskinesia [46]. The use of telemedicine to offer
“virtual house calls” for PD has been suggested to be
comparable to in-office visits as it is feasible, cost-effective,
and acceptable to patients [47, 48]. The potential pool of
patients that may benefit from telemedicine is therefore re-
markable. In addition to an improved access to specialized
care, telemedicine-based protocols may foster participation
in clinical trials and provide meaningful observational data
on the natural course of disease in the most advanced
stages [49]. Without effectively reaching those patients
burdened by higher disability and clinical severity, it is diffi-
cult to carry out inclusive research protocols and validate
optimal therapies [50].
Tele-monitored tDCS evidence in Parkinson’s disease
We reviewed the state of research on tele-tDCS applied to
patients affected by PD. The research included the follow-
ing databases: Pubmed, Google Scholar, Scopus, Semantic
Scholar, Clinical Trials.gov and Research Gate. The terms
“remotely-supervised”, “at-home”, “domiciliary”, “tele-mo-
nitored”, “telehealth” and “telemedicine” were searched in
cross-combination with “Parkinson’s Disease” and “trans-
cranial direct current stimulation”. We found three studies
regarding the use of telemedicine-based tDCS in this spe-
cific population.
Shaw and colleagues published the first feasibility and
safety trial with a paradigm of remotely supervised tDCS
(RS-tDCS) that included six PD patients in 2017. The
study reported feasibility and safety of RS-tDCS over 10
daily sessions paired with computer-based cognitive
training in 52 patients. Of the 60 RS-tDCS sessions in
PD participants, side effects did not differ from com-
monly reported side effects of conventional tDCS [41].
The authors of the present review have recently com-
pleted an exploratory, open label study of remotely super-
vised anodal tDCS over the left DLPFC paired with
cognitive training in PD participants [51]. Based on the
methods of Shaw et al., each participant completed 10 daily
RS-tDCS sessions (20-min, 1.5–2.0-mA, bi-hemispheric
DLPFC montage, left anodal), over a span of 2 weeks. The
study enrolled 16 PD participants with moderate disease
severity. One participant terminated early from the study
due to exertional angina that resolved after a stenting pro-
cedure; this was deemed unrelated to the study. A total of
152 RS-tDCS sessions were completed during the study,
with 100% compliance and only mild adverse events pro-
viding evidence in favor of the feasibility and safety of
tele-rehabilitation in PD participants. In terms of clinical
outcomes, a small but significant improvement in both
motor scores and total scores of the Unified Parkinson’s
Disease Rating Scale was observed (a widely used scale for
quantification of PD cumulative disability). Within motor
scores, the greatest improvement was in axial/balance
symptoms. Importantly, axial/balance symptoms including
gait failure are often unresponsive to optimal pharmaco-
logical treatments and are known to be poor prognostic
factors in PD. Agarwal et al. acknowledged several study
limitations inherent to the open-label, exploratory de-
sign, which does not allow controlling for placebo ef-
fect. Further limitations include the small sample size
and the absence of a long-term follow-up assessment.
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However, the results of this study provided further evi-
dence supporting the feasibility and safe therapeutic appli-
cation of tele-tDCS in patients PD.
After the successful completion of the first open label
exploratory study, our group is conducting an ongoing
double-blind, pilot, RCT testing the effects of RS-tDCS
using a DLPFC montage to ameliorate fatigue and cog-
nitive slowing in PD (https://clinicaltrials.gov/show/
NCT03189472). The protocol involves 10 daily sessions
of bi-frontal 20-min RS-tDCS (2 mA, F3-F4 montage,
left anodal) followed by an optional open label phase
consisting of 10 additional sessions. Seventeen participants
completed 330 tele-tDCS sessions (170 double blind and
160 open label). Preliminary feasibility and safety results
showed no serious adverse events, only mild to moderate
side effects and 100% compliance. All participants but one
opted to undergo the open label phase [52].
Pooling the available safety data in PD from both studies
together, totaling 482 tele-tDCS sessions, the side effects
and adverse events were similar than previously published
studies performing conventional tDCS in lab settings
(Fig. 3), with the exception of a single severe adverse event
which was deemed unrelated to study procedures. Based
on these preliminary results, at-home RS-tDCS therapy
seems acceptable and well tolerated in this population,
with the advantages of ease of recruitment and subject re-
tention. Data regarding the efficacy of this technology to
ameliorate fatigue and cognitive slowing in PD is still
pending upon completion of the study.
Specific challenges inherent to Parkinson’s disease
population
Telemedicine protocols may be intimidating to those
who are not familiar with the technology, and cognitive
impairment is a common finding in advanced PD. Partici-
pation of such patients has been shown to be increased by
the availability of caregivers agreeable to be trained in the
use of the equipment and assist the patient during sessions.
In selected populations (e.g. limited mobility, co-morbid
dementia), the support of a caregiver, spouse or significant
other might be important for tele-tDCS paradigms. In-
creased caregiver’s burden is a well-documented occurrence
in PD [53]. This factor must be considered in the imple-
mentation of tele-tDCS protocols, as additional responsibil-
ities may further challenge caregivers’ strain.
Fluctuating motor performance, severe and/or unpre-
dictable OFF states, severe freezing and bothersome
dyskinesia or tremor could also be present temporarily
in a given patient. Special precautions (e.g. providing
video-conferencing platforms to detect these states) and
schedule flexibility to conduct sessions might improve
compliance, safety and tolerability in these particular
cases.
Finally, from an experimental viewpoint, patient’s pharma-
cological state while receiving tDCS neuromodulation can
affect the brain activation state and connectivity by modulat-
ing neuronal propensity to fire and undergo plastic phenom-
ena. In patients with PD, this is particularly noteworthy,
as changes in cortical excitability and neuroplasticity
are critically influenced by dopamine bioavailability, and
the institution of a dopaminergic therapy can influence the
subsequent neurophysiologic and behavioral effects of
stimulation [54]. The potential influence of subject’s contin-
gent dopaminergic state should be carefully considered
when implementing experimental tDCS protocols and a
rigorous control of patient’s pharmacological state, particu-
larly in subjects experiencing motor fluctuations, should be
always pursued.
Fig. 3 Pooled data of frequency of adverse events experienced with remotely supervised tDCS (RS-tDCS) under real time video-conferencing in
Parkinson’s disease patients. Presented here, a total of 312 sessions for open label (OpL), 90 sessions for double blind real (DB), and 80 sessions
for DB sham. During sham tDCS, patients received only 60 s of stimulation at the beginning and at the end of the 20 min tDCS sessions
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Future perspectives
The broad application of non-invasive brain stimulation
techniques, including tDCS, is currently limited by dif-
ferent factors. First, the body of the available evidence
still rests on small-sized studies carried out with ex-
ploratory designs. As such, these studies are known to
be particularly prone to the risk of type I and type II
statistical errors. A second order of limitation is posed
by the high heterogeneity of stimulation parameters and
methods between the published trials. These differences
result in a limited comparability between the various ex-
perimental protocols. Finally, a third important constrain
is the paucity of studies with multiple tDCS sessions (i.e.
beyond 10 sessions) as the current evidence suggests
higher chances of harnessing cumulative biological ef-
fects following multiple sessions of stimulation over
time. The development of tele-tDCS paradigms may spe-
cifically address some of these challenges improving
protocol standardization and adherence while minimiz-
ing attrition. This may be particularly noteworthy in
patients burdened by chronic motor disability or living
in remote geographic areas. In the near future, the
broad availability of different communication technolo-
gies may favor the implementation of new personalized
models of care in neurology and rehabilitation. In this
setting, the therapeutic value and overall safety of
tele-tDCS remain to be determined through appropri-
ately designed trials. The current limited evidence sug-
gests high acceptance rate and overall optimal
feasibility but further studies are needed to corroborate
these preliminary findings.
Conclusions
tDCS is a relatively safe and tolerable non-invasive
neuro-modulation technique that could be incorporated
into telemedicine protocols in light of its portability and
easy operability. The use of tele-tDCS within standardized
frameworks ensuring safety, tolerability, and reproducibility
in adequately selected patients may expand access to care
and allow for the inclusion of larger populations into clin-
ical trials while minimizing attrition and improving cost/ef-
fectiveness. Most patients affected by PD worldwide face
multiple barriers preventing a consistent access to special-
ized, effective, and interdisciplinary care. Current evidence
supports feasibility and safety of tele-tDCS protocols in the
setting of remotely supervised videoconference sessions
delivered to patients affected by PD. In these patients,
specific challenges to the extensive implementation of
tele-tDCS include the possibility of motor and non-motor
fluctuations, cognitive deficits, polypharmacy, psychiatric
comorbidities and risk of caregiver’s burden. Although the
safety and feasibility of these protocols in PD patients await
further validation, preliminary data seem to suggest optimal
adherence and acceptability in this particular patient
population opening the field for larger research initiatives
needed to define the therapeutic potential of this
intervention.
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